Cargando…
Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether‐à‐go‐go–Related Gene and Cav1.2
Background: Old drugs for new indications in the novel coronavirus disease of 2019 (COVID-19) pandemic have raised concerns regarding cardiotoxicity, especially the development of drug-induced QT prolongation. The acute blocking of the cardiac hERG potassium channel is conventionally thought to be t...
Autores principales: | Zheng, Zequn, Cai, Dihui, Fu, Yin, Wang, Ying, Song, Yongfei, Lian, Jiangfang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301601/ https://www.ncbi.nlm.nih.gov/pubmed/35873575 http://dx.doi.org/10.3389/fphar.2022.889713 |
Ejemplares similares
-
Molecular Insights Into the Gating Kinetics of the Cardiac hERG Channel, Illuminated by Structure and Molecular Dynamics
por: Zequn, Zheng, et al.
Publicado: (2021) -
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel
por: Zequn, Zheng, et al.
Publicado: (2021) -
Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
por: Sukhatme, Vikas P., et al.
Publicado: (2021) -
4-phenylbutyric acid re-trafficking hERG/G572R channel protein by modulating the endoplasmic reticulum stress-associated chaperones and endoplasmic reticulum-associated degradation gene
por: Tang, Wen, et al.
Publicado: (2023) -
Cardiac safety assessment of a novel recombinant bispecific antibody targeting the ether-à-go-go related gene 1 (hERG1)-β1 integrin macromolecular complex
por: Santini, Lorenzo, et al.
Publicado: (2023)